SREBF1 and steatosis: Taken together, LXR activation has dual effects: it mitigates atherosclerosis by promoting RCT and suppressing inflammation, but drives hypertriglyceridemia and steatosis by inducing SREBP-1c-dependent hepatic lipogenesis.